In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global Phase 2 trial of KAI-7535 in obesity to further optimize KAI-7535's clinical profile for the
Company expands executive team with strategic corporate affairs leader as it advances its differentiated obesity portfolio WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean
WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, will present at the 2026 Jefferies Global
Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 program Reported positive topline clinical data from three trials conducted by
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the closing of its initial public offering of 44,921,875 shares of its common
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the pricing of its initial public offering of 39,062,500 shares of its common
Mean weight loss of up to 12.1% with no observed plateau at 26 weeks in Phase 2 trial in China with oral GLP-1/GIP receptor dual agonist ribupatide Up to 38.6% of participants taking oral ribupatide achieved at least 15% weight loss Vomiting reported in 11.4% and 7.5% of participants taking 25 mg
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m 2 or greater KaiNETIC program includes three Phase 3 clinical trials in adults living with obesity or overweight Waltham, MA, January 12, 2026 — Kailera Therapeutics,
